IngentaConnect Urinary leukotriene E4 in Henoch-Schonlein purpura

Authors: Y. Tsuji; Y. Abe¹; M. Hisano¹; T. Sakai²

Source: Clinical & Experimental Allergy, Volume 34, Number 8, August 2004 , pp. 1259-1261(3)

Abstract:

Summary Background

Children with Henoch–Schonlein purpura (HSP) occasionally have allergic disease. We have previously shown that pranlukast hydrate was effective for purpura in HSP. Pranlukast hydrate is a leukotriene (LT) receptor antagonist; therefore, it is likely that LTs take part in the cause of HSP. Urinary leukotriene E₄ (LTE₄u) levels are a useful index of whole-body cysteinyl LT production in vivo. In this study, LTE₄u was examined in children with HSP. Objective

The purpose of this study was to examine the relation between the level of LTE₄u and the cause of HSP. Methods

Eighteen HSP children (six boys and 12 girls) and six healthy children were enrolled. Results

LTE₄u levels in patients with HSP were significantly higher (P<0.05) at the onset than those in healthy children. Four weeks therapy with pranlukast hydrate lowers LTE₄u levels in patients with HSP (P<0.05). There were no differences in LTE₄u between the group of HSP patients with purpura nephritis and the group of HSP patients without purpura nephritis. Conclusion

These results indicate that csyteinyl LTs may play a role in the pathophysiology of purpura in HSP.

Keywords: cysteinyl leukotriene; Henoch–Schonlein purpura; leukotriene E4; pranlukast hydrate

Document Type: Research article

DOI: 10.1111/j.1365-2222.2004.02029.x

Affiliations: 1: Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan, 2: Children Kidney Center, Yokohama, Japan

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy

Urinary leukotriene E4 in Henoch–Schonlein purpura

Urinary leukotriene E₄ in Henoch–Schonlein purpura